Copyright Reports & Markets. All rights reserved.

Global Oligonucleotide Drug Delivery Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Oligonucleotide Drug Delivery
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Oligonucleotide Drug Delivery by Type
    • 1.3.1 Overview: Global Oligonucleotide Drug Delivery Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Oligonucleotide Drug Delivery Consumption Value Market Share by Type in 2022
    • 1.3.3 Antisense Oligonucleotides (ASO)
    • 1.3.4 siRNA
    • 1.3.5 mRNA
  • 1.4 Global Oligonucleotide Drug Delivery Market by Application
    • 1.4.1 Overview: Global Oligonucleotide Drug Delivery Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Neuromuscular Diseases
    • 1.4.3 hATTR
    • 1.4.4 COVID-19
    • 1.4.5 Other
  • 1.5 Global Oligonucleotide Drug Delivery Market Size & Forecast
  • 1.6 Global Oligonucleotide Drug Delivery Market Size and Forecast by Region
    • 1.6.1 Global Oligonucleotide Drug Delivery Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Oligonucleotide Drug Delivery Market Size by Region, (2018-2029)
    • 1.6.3 North America Oligonucleotide Drug Delivery Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Oligonucleotide Drug Delivery Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Oligonucleotide Drug Delivery Market Size and Prospect (2018-2029)
    • 1.6.6 South America Oligonucleotide Drug Delivery Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Oligonucleotide Drug Delivery Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Sarepta Therapeutics
    • 2.1.1 Sarepta Therapeutics Details
    • 2.1.2 Sarepta Therapeutics Major Business
    • 2.1.3 Sarepta Therapeutics Oligonucleotide Drug Delivery Product and Solutions
    • 2.1.4 Sarepta Therapeutics Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
  • 2.2 Ionis Pharmaceuticals
    • 2.2.1 Ionis Pharmaceuticals Details
    • 2.2.2 Ionis Pharmaceuticals Major Business
    • 2.2.3 Ionis Pharmaceuticals Oligonucleotide Drug Delivery Product and Solutions
    • 2.2.4 Ionis Pharmaceuticals Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
  • 2.3 Alnylam
    • 2.3.1 Alnylam Details
    • 2.3.2 Alnylam Major Business
    • 2.3.3 Alnylam Oligonucleotide Drug Delivery Product and Solutions
    • 2.3.4 Alnylam Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Alnylam Recent Developments and Future Plans
  • 2.4 Biogen
    • 2.4.1 Biogen Details
    • 2.4.2 Biogen Major Business
    • 2.4.3 Biogen Oligonucleotide Drug Delivery Product and Solutions
    • 2.4.4 Biogen Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Biogen Recent Developments and Future Plans
  • 2.5 Nippon Shinyaku
    • 2.5.1 Nippon Shinyaku Details
    • 2.5.2 Nippon Shinyaku Major Business
    • 2.5.3 Nippon Shinyaku Oligonucleotide Drug Delivery Product and Solutions
    • 2.5.4 Nippon Shinyaku Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Nippon Shinyaku Recent Developments and Future Plans
  • 2.6 Sobi
    • 2.6.1 Sobi Details
    • 2.6.2 Sobi Major Business
    • 2.6.3 Sobi Oligonucleotide Drug Delivery Product and Solutions
    • 2.6.4 Sobi Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Sobi Recent Developments and Future Plans
  • 2.7 Novartis
    • 2.7.1 Novartis Details
    • 2.7.2 Novartis Major Business
    • 2.7.3 Novartis Oligonucleotide Drug Delivery Product and Solutions
    • 2.7.4 Novartis Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Novartis Recent Developments and Future Plans
  • 2.8 BioNTech
    • 2.8.1 BioNTech Details
    • 2.8.2 BioNTech Major Business
    • 2.8.3 BioNTech Oligonucleotide Drug Delivery Product and Solutions
    • 2.8.4 BioNTech Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 BioNTech Recent Developments and Future Plans
  • 2.9 Pfizer
    • 2.9.1 Pfizer Details
    • 2.9.2 Pfizer Major Business
    • 2.9.3 Pfizer Oligonucleotide Drug Delivery Product and Solutions
    • 2.9.4 Pfizer Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Pfizer Recent Developments and Future Plans
  • 2.10 Moderna Therapeutics
    • 2.10.1 Moderna Therapeutics Details
    • 2.10.2 Moderna Therapeutics Major Business
    • 2.10.3 Moderna Therapeutics Oligonucleotide Drug Delivery Product and Solutions
    • 2.10.4 Moderna Therapeutics Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Moderna Therapeutics Recent Developments and Future Plans
  • 2.11 Jazz Pharmaceuticals
    • 2.11.1 Jazz Pharmaceuticals Details
    • 2.11.2 Jazz Pharmaceuticals Major Business
    • 2.11.3 Jazz Pharmaceuticals Oligonucleotide Drug Delivery Product and Solutions
    • 2.11.4 Jazz Pharmaceuticals Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.12 CureVac
    • 2.12.1 CureVac Details
    • 2.12.2 CureVac Major Business
    • 2.12.3 CureVac Oligonucleotide Drug Delivery Product and Solutions
    • 2.12.4 CureVac Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 CureVac Recent Developments and Future Plans
  • 2.13 Regulus Therapeutics
    • 2.13.1 Regulus Therapeutics Details
    • 2.13.2 Regulus Therapeutics Major Business
    • 2.13.3 Regulus Therapeutics Oligonucleotide Drug Delivery Product and Solutions
    • 2.13.4 Regulus Therapeutics Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Regulus Therapeutics Recent Developments and Future Plans
  • 2.14 ProQR
    • 2.14.1 ProQR Details
    • 2.14.2 ProQR Major Business
    • 2.14.3 ProQR Oligonucleotide Drug Delivery Product and Solutions
    • 2.14.4 ProQR Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 ProQR Recent Developments and Future Plans
  • 2.15 Secarna
    • 2.15.1 Secarna Details
    • 2.15.2 Secarna Major Business
    • 2.15.3 Secarna Oligonucleotide Drug Delivery Product and Solutions
    • 2.15.4 Secarna Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Secarna Recent Developments and Future Plans
  • 2.16 MiNA Therapeutics
    • 2.16.1 MiNA Therapeutics Details
    • 2.16.2 MiNA Therapeutics Major Business
    • 2.16.3 MiNA Therapeutics Oligonucleotide Drug Delivery Product and Solutions
    • 2.16.4 MiNA Therapeutics Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 MiNA Therapeutics Recent Developments and Future Plans
  • 2.17 Sylentis
    • 2.17.1 Sylentis Details
    • 2.17.2 Sylentis Major Business
    • 2.17.3 Sylentis Oligonucleotide Drug Delivery Product and Solutions
    • 2.17.4 Sylentis Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 Sylentis Recent Developments and Future Plans
  • 2.18 Arrowhead
    • 2.18.1 Arrowhead Details
    • 2.18.2 Arrowhead Major Business
    • 2.18.3 Arrowhead Oligonucleotide Drug Delivery Product and Solutions
    • 2.18.4 Arrowhead Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.18.5 Arrowhead Recent Developments and Future Plans
  • 2.19 Silence Therapeutics
    • 2.19.1 Silence Therapeutics Details
    • 2.19.2 Silence Therapeutics Major Business
    • 2.19.3 Silence Therapeutics Oligonucleotide Drug Delivery Product and Solutions
    • 2.19.4 Silence Therapeutics Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.19.5 Silence Therapeutics Recent Developments and Future Plans
  • 2.20 Dicerna
    • 2.20.1 Dicerna Details
    • 2.20.2 Dicerna Major Business
    • 2.20.3 Dicerna Oligonucleotide Drug Delivery Product and Solutions
    • 2.20.4 Dicerna Oligonucleotide Drug Delivery Revenue, Gross Margin and Market Share (2018-2023)
    • 2.20.5 Dicerna Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Oligonucleotide Drug Delivery Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Oligonucleotide Drug Delivery by Company Revenue
    • 3.2.2 Top 3 Oligonucleotide Drug Delivery Players Market Share in 2022
    • 3.2.3 Top 6 Oligonucleotide Drug Delivery Players Market Share in 2022
  • 3.3 Oligonucleotide Drug Delivery Market: Overall Company Footprint Analysis
    • 3.3.1 Oligonucleotide Drug Delivery Market: Region Footprint
    • 3.3.2 Oligonucleotide Drug Delivery Market: Company Product Type Footprint
    • 3.3.3 Oligonucleotide Drug Delivery Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Oligonucleotide Drug Delivery Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Oligonucleotide Drug Delivery Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Oligonucleotide Drug Delivery Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Oligonucleotide Drug Delivery Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Oligonucleotide Drug Delivery Consumption Value by Type (2018-2029)
  • 6.2 North America Oligonucleotide Drug Delivery Consumption Value by Application (2018-2029)
  • 6.3 North America Oligonucleotide Drug Delivery Market Size by Country
    • 6.3.1 North America Oligonucleotide Drug Delivery Consumption Value by Country (2018-2029)
    • 6.3.2 United States Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Oligonucleotide Drug Delivery Consumption Value by Type (2018-2029)
  • 7.2 Europe Oligonucleotide Drug Delivery Consumption Value by Application (2018-2029)
  • 7.3 Europe Oligonucleotide Drug Delivery Market Size by Country
    • 7.3.1 Europe Oligonucleotide Drug Delivery Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 7.3.3 France Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Oligonucleotide Drug Delivery Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Oligonucleotide Drug Delivery Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Oligonucleotide Drug Delivery Market Size by Region
    • 8.3.1 Asia-Pacific Oligonucleotide Drug Delivery Consumption Value by Region (2018-2029)
    • 8.3.2 China Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 8.3.5 India Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Oligonucleotide Drug Delivery Consumption Value by Type (2018-2029)
  • 9.2 South America Oligonucleotide Drug Delivery Consumption Value by Application (2018-2029)
  • 9.3 South America Oligonucleotide Drug Delivery Market Size by Country
    • 9.3.1 South America Oligonucleotide Drug Delivery Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Oligonucleotide Drug Delivery Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Oligonucleotide Drug Delivery Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Oligonucleotide Drug Delivery Market Size by Country
    • 10.3.1 Middle East & Africa Oligonucleotide Drug Delivery Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Oligonucleotide Drug Delivery Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Oligonucleotide Drug Delivery Market Drivers
  • 11.2 Oligonucleotide Drug Delivery Market Restraints
  • 11.3 Oligonucleotide Drug Delivery Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Oligonucleotide Drug Delivery Industry Chain
  • 12.2 Oligonucleotide Drug Delivery Upstream Analysis
  • 12.3 Oligonucleotide Drug Delivery Midstream Analysis
  • 12.4 Oligonucleotide Drug Delivery Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Oligonucleotide Drug Delivery market size was valued at USD 65800 million in 2022 and is forecast to a readjusted size of USD 84010 million by 2029 with a CAGR of 3.6% during review period.
    Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
    The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
    The Global Info Research report includes an overview of the development of the Oligonucleotide Drug Delivery industry chain, the market status of Neuromuscular Diseases (Antisense Oligonucleotides (ASO), siRNA), hATTR (Antisense Oligonucleotides (ASO), siRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Oligonucleotide Drug Delivery.
    Regionally, the report analyzes the Oligonucleotide Drug Delivery markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Oligonucleotide Drug Delivery market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Oligonucleotide Drug Delivery market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Oligonucleotide Drug Delivery industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO), siRNA).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Oligonucleotide Drug Delivery market.
    Regional Analysis: The report involves examining the Oligonucleotide Drug Delivery market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Oligonucleotide Drug Delivery market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Oligonucleotide Drug Delivery:
    Company Analysis: Report covers individual Oligonucleotide Drug Delivery players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Oligonucleotide Drug Delivery This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Neuromuscular Diseases, hATTR).
    Technology Analysis: Report covers specific technologies relevant to Oligonucleotide Drug Delivery. It assesses the current state, advancements, and potential future developments in Oligonucleotide Drug Delivery areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Oligonucleotide Drug Delivery market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Oligonucleotide Drug Delivery market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Antisense Oligonucleotides (ASO)
    siRNA
    mRNA
    Market segment by Application
    Neuromuscular Diseases
    hATTR
    COVID-19
    Other
    Market segment by players, this report covers
    Sarepta Therapeutics
    Ionis Pharmaceuticals
    Alnylam
    Biogen
    Nippon Shinyaku
    Sobi
    Novartis
    BioNTech
    Pfizer
    Moderna Therapeutics
    Jazz Pharmaceuticals
    CureVac
    Regulus Therapeutics
    ProQR
    Secarna
    MiNA Therapeutics
    Sylentis
    Arrowhead
    Silence Therapeutics
    Dicerna
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Oligonucleotide Drug Delivery product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Oligonucleotide Drug Delivery, with revenue, gross margin and global market share of Oligonucleotide Drug Delivery from 2018 to 2023.
    Chapter 3, the Oligonucleotide Drug Delivery competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Oligonucleotide Drug Delivery market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Oligonucleotide Drug Delivery.
    Chapter 13, to describe Oligonucleotide Drug Delivery research findings and conclusion.

    Buy now